213 related articles for article (PubMed ID: 34652783)
1. Does a lack of vaccine side effects correlate with reduced BNT162b2 mRNA vaccine response among healthcare workers and nursing home residents?
Oyebanji OA; Wilson B; Keresztesy D; Carias L; Wilk D; Payne M; Aung H; Denis KS; Lam EC; Rowley CF; Berry SD; Cameron CM; Cameron MJ; Schmader KE; Balazs AB; King CL; Canaday DH; Gravenstein S
Aging Clin Exp Res; 2021 Nov; 33(11):3151-3160. PubMed ID: 34652783
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity, effectiveness and safety of COVID-19 vaccine in older adults living in nursing homes: A real-life study.
Meijide Míguez H; Montes García I; Ochando Gómez M; García Merino IM; Cano EL; De La Torre A
Rev Esp Geriatr Gerontol; 2023; 58(3):125-133. PubMed ID: 37031072
[TBL] [Abstract][Full Text] [Related]
3. Pronounced antibody elevation after SARS-CoV-2 BNT162b2 mRNA booster vaccination in nursing home residents.
Chong Y; Goto T; Tani N; Yonekawa A; Ikematsu H; Shimono N; Tanaka Y; Akashi K
Influenza Other Respir Viruses; 2022 Nov; 16(6):1066-1071. PubMed ID: 35962568
[TBL] [Abstract][Full Text] [Related]
4. Humoral immunity induced by mRNA COVID-19 vaccines in Nursing Home Residents previously infected with SARS-CoV-2.
Fedele G; Palmieri A; Damiano C; Di Lonardo A; Leone P; Schiavoni I; Trevisan C; Abbatecola AM; Cafariello C; Malara A; Minchella P; Panduri G; Antonelli Incalzi R; Palamara AT; Stefanelli P; Onder G;
Aging Clin Exp Res; 2022 Oct; 34(10):2577-2584. PubMed ID: 36127623
[TBL] [Abstract][Full Text] [Related]
5. Reduced BNT162b2 Messenger RNA Vaccine Response in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Naive Nursing Home Residents.
Canaday DH; Carias L; Oyebanji OA; Keresztesy D; Wilk D; Payne M; Aung H; St Denis K; Lam EC; Rowley CF; Berry SD; Cameron CM; Cameron MJ; Wilson B; Balazs AB; Gravenstein S; King CL
Clin Infect Dis; 2021 Dec; 73(11):2112-2115. PubMed ID: 33993265
[TBL] [Abstract][Full Text] [Related]
6. COVID-19 vaccine booster dose needed to achieve Omicron-specific neutralisation in nursing home residents.
Canaday DH; Oyebanji OA; White E; Keresztesy D; Payne M; Wilk D; Carias L; Aung H; St Denis K; Sheehan ML; Berry SD; Cameron CM; Cameron MJ; Wilson BM; Balazs AB; King CL; Gravenstein S
EBioMedicine; 2022 Jun; 80():104066. PubMed ID: 35605428
[TBL] [Abstract][Full Text] [Related]
7. Impact of prior infection status on antibody response to the BNT162b2 mRNA COVID-19 vaccine in healthcare workers at a COVID-19 referral hospital in Milan, Italy.
Milazzo L; Pezzati L; Oreni L; Kullmann C; Lai A; Gabrieli A; Bestetti G; Beschi C; Conti F; Ottomano C; Gervasoni C; Meroni L; Galli M; Antinori S; Ridolfo AL
Hum Vaccin Immunother; 2021 Dec; 17(12):4747-4754. PubMed ID: 35086438
[TBL] [Abstract][Full Text] [Related]
8. Safety, Effectiveness, and Immunogenicity 6 Months After BNT162B2 mRNA Vaccine in Frail Nursing Home Residents.
Montejano-Hervás P; Gómez-Pavón J; Tornero-Torres O; Valverde-Moyar MV; Martín Cruz B; Vela Carbonera M; Fuentes-Irigoyen R; Tejada González P; González-Becerra M; Higueras Sánchez E; Ramos Cordero P
Drugs Aging; 2022 Jul; 39(7):587-595. PubMed ID: 35794430
[TBL] [Abstract][Full Text] [Related]
9. Reactogenicity among health care workers following a BNT162b2 or mRNA-1273 second dose after priming with a ChAdOx1 nCOV-19 vaccine.
Baldolli A; Fournier A; Verdon R; Michon J
Clin Microbiol Infect; 2022 Jun; 28(6):885.e1-885.e5. PubMed ID: 35182759
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of immunogenicity and reactogenicity of COVID-19 vaccines in pregnant women.
Blakeway H; Amin-Chowdhury Z; Prasad S; Kalafat E; Ismail M; Abdallah FN; Rezvani A; Amirthalingam G; Brown K; Le Doare K; Heath PT; Ladhani SN; Khalil A
Ultrasound Obstet Gynecol; 2022 Nov; 60(5):673-680. PubMed ID: 36318630
[TBL] [Abstract][Full Text] [Related]
11. Significant Reduction in Vaccine-Induced Antibody Levels and Neutralization Activity Among Healthcare Workers and Nursing Home Residents 6 Months Following Coronavirus Disease 2019 BNT162b2 mRNA Vaccination.
Canaday DH; Oyebanji OA; Keresztesy D; Payne M; Wilk D; Carias L; Aung H; St Denis K; Lam EC; Rowley CF; Berry SD; Cameron CM; Cameron MJ; Wilson BM; Balazs AB; King CL; Gravenstein S
Clin Infect Dis; 2022 Aug; 75(1):e884-e887. PubMed ID: 35174389
[TBL] [Abstract][Full Text] [Related]
12. Associations of BNT162b2 vaccination with SARS-CoV-2 infection and hospital admission and death with covid-19 in nursing homes and healthcare workers in Catalonia: prospective cohort study.
Cabezas C; Coma E; Mora-Fernandez N; Li X; Martinez-Marcos M; Fina F; Fabregas M; Hermosilla E; Jover A; Contel JC; Lejardi Y; Enfedaque B; Argimon JM; Medina-Peralta M; Prieto-Alhambra D
BMJ; 2021 Aug; 374():n1868. PubMed ID: 34407952
[TBL] [Abstract][Full Text] [Related]
13. Reactogenicity and immunogenicity of BNT162b2 or mRNA-1273 COVID-19 booster vaccinations after two doses of BNT162b2 among healthcare workers in Japan: a prospective observational study.
Naito T; Tsuchida N; Kusunoki S; Kaneko Y; Tobita M; Hori S; Ito S
Expert Rev Vaccines; 2022 Sep; 21(9):1319-1329. PubMed ID: 35763290
[TBL] [Abstract][Full Text] [Related]
14. [Humoral immunity against SARS-CoV-2 in workers of social health care centers of Castilla y León after vaccination with the BNT162b2 mRNA vaccine from Pfizer/Biontech.].
Casas Fischer R
Rev Esp Salud Publica; 2021 Oct; 95():. PubMed ID: 34690347
[TBL] [Abstract][Full Text] [Related]
15. BNT162b2 mRNA COVID-19 vaccine Reactogenicity: The key role of immunity.
Vizcarra P; Haemmerle J; Velasco H; Velasco T; Fernández-Escribano M; Vallejo A; Casado JL
Vaccine; 2021 Dec; 39(51):7367-7374. PubMed ID: 34802792
[TBL] [Abstract][Full Text] [Related]
16. Reactogenicity following two doses of the BNT162b2 mRNA COVID-19 vaccine: Real-world evidence from healthcare workers in Japan.
Saita M; Yan Y; Ito K; Sasano H; Seyama K; Naito T
J Infect Chemother; 2022 Jan; 28(1):116-119. PubMed ID: 34580011
[TBL] [Abstract][Full Text] [Related]
17. Anti-spike IgG antibody kinetics following the second and third doses of BNT162b2 vaccine in nursing home residents.
Jeulin H; Labat C; Duarte K; Toupance S; Nadin G; Craus D; Georgiopoulos I; Gantois I; Goehringer F; Benetos A
J Am Geriatr Soc; 2022 Sep; 70(9):2552-2560. PubMed ID: 35484977
[TBL] [Abstract][Full Text] [Related]
18. Reduced BNT162b2 mRNA vaccine response in SARS-CoV-2-naive nursing home residents.
Canaday DH; Carias L; Oyebanji OA; Keresztesy D; Wilk D; Payne M; Aung H; St Denis K; Lam EC; Wilson B; Rowley CF; Berry SD; Cameron CM; Cameron MJ; Balazs AB; Gravenstein S; King CL
medRxiv; 2021 Mar; ():. PubMed ID: 33791727
[TBL] [Abstract][Full Text] [Related]
19. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
Front Immunol; 2022; 13():827306. PubMed ID: 35173736
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects.
Pham MN; Murugesan K; Banaei N; Pinsky BA; Tang M; Hoyte E; Lewis DB; Gernez Y
J Allergy Clin Immunol; 2022 Mar; 149(3):907-911.e3. PubMed ID: 34952033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
